Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Lonza | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Lonza

Pharma & Biotech segment sales up

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Lonza

1H13: Lonza reported growth of approximately 10%, with Pharma & Biotech segment sales of CHF 609 million.
 
Comments: In the Manufacturing segment, several segments experienced growth, including microbial and mammalian technology offerings, and integrated ADC offerings, as well as new contracts for small molecule products. Custom Development growth was attributed to the mammalian business and expanded microbial capabilities, as well as cell therapy process development services. Bioscience Solutions growth was driven by the progressing long-term Sartorius collaboration and Endotoxin sales, offset by research products facing challenging market environment and competition in Europe and the U.S. Specialty ingredients market sales were CHF 1.1 billion and include Consumer Care, Agro Ingredients, Water Treatment, Wood Protection, and Industrial Solutions. At the end of September Lonza reduced its overall headcount by 744 positions.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics